Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which antibiotic wins for liver infection? new study compares ciprofloxacin and ceftriaxone

NCT ID NCT07552870

Disease control Sponsor: Shahida Islam Medical Complex Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two antibiotics—ciprofloxacin and ceftriaxone—given intravenously to 310 patients with liver cirrhosis who developed a serious infection called spontaneous bacterial peritonitis. The goal was to see which drug better controlled fever, abdominal pain, and infection markers after 48 hours. The trial has completed, and results may help guide treatment choices for this life-threatening condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ciprofloxacin and ceftriaxone (antibiotics given intravenously)
What this could lead to
If one antibiotic proves more effective, it could become the preferred treatment for this serious infection in cirrhosis patients, potentially reducing hospital deaths.
What could go wrong
This is a single-center study with a moderate number of participants. Results may not apply to all patients, and both antibiotics have known side effects like allergic reactions or antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

310 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient diagnosed with spontaneous bacterial peritonitis: Child Pugh class A, B and C, confirmed from record file of the patient. Male and female patients from the age of 25-70 years with liver cirrhosis Exclusion Criteria: * Hemorrhagic or malignant ascites. (on history). * Tuberculous with secondary peritonitis (on medical record file). * Hepatocellular carcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis infectious peritonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis

Contacts and locations

Locations

  • Nishtar Hospital

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.